Psoriasis and eczema clinic marketing: cure and clear skin claims, creams, photos and referrals

A psoriasis or eczema clinic speaks to people who have lived with itching that keeps them up at night, patches they hide under long sleeves, or a child who scratches until the skin bleeds. The program may sit inside a dermatology practice, an allergy practice, a pediatric practice or a rheumatology group that also sees the joint side of psoriasis. This guide covers what the federal sources say about psoriasis and atopic dermatitis, how to write about treatment without promising a cure or clear skin for good, where a cream crosses the line from cosmetic to drug, how to handle the 911 and call-us lines, photos, and money from partners.

Six related topics have their own guides and are not repeated here. General skin practice marketing, including the split between medical and cosmetic pages, is covered in our guide to dermatology practice marketing, and psoriatic arthritis, defined treatment terms and copay programs in our guide to rheumatology practice marketing. Skin checks and Mohs surgery are covered in our guide to skin cancer clinic marketing, and allergy testing in our guides to food allergy clinic marketing and ENT and allergy practice marketing. Children’s care in general is covered in our guide to pediatric practice marketing. Vitiligo creams and excimer light are covered in our guide to vitiligo treatment advertising.

What NIAMS and MedlinePlus say

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) leads federal research on both conditions, and MedlinePlus from the National Library of Medicine publishes the federal patient pages. The points that shape a clinic’s marketing:

• The NIAMS Psoriasis page (last reviewed October 2023, older than two years) calls psoriasis a chronic (long-lasting) disease in which the immune system becomes overactive and skin cells multiply too quickly. It says the treatment plan depends on the type and severity of disease, that mild psoriasis can be treated with creams or ointments, and that moderate and severe psoriasis may require pills, injections or light treatments. It says symptoms can get worse in flares followed by times when people feel better.
• The same NIAMS page says psoriasis carries the risk of other serious conditions, including psoriatic arthritis, heart attacks and strokes, and mental health problems such as low self-esteem, anxiety and depression. It says that untreated psoriatic arthritis can lead to irreversible damage and that a person with joint symptoms should see their doctor soon.
• The NIAMS Psoriasis: Diagnosis, Treatment, and Steps to Take page (last reviewed October 2023) says that while there is currently no cure for psoriasis, there are treatments that keep symptoms under control. It says limited sunlight can ease symptoms but too much can make them worse, so people should ask their doctor. The NIAMS Psoriatic Arthritis page (last reviewed August 2024) says there is no cure for psoriatic arthritis and that treatments can slow its progression, lessen pain and protect the joints.
• The NIAMS Atopic Dermatitis page (last reviewed November 2022, older than two years) says atopic dermatitis, also called eczema, is a chronic disease that causes inflammation, redness and irritation of the skin, that it is not contagious, and that treatment can help control symptoms. It describes flares followed by remissions, says atopic dermatitis goes away before the teenage years for a large number of children while others keep symptoms as teens and adults, and lists asthma, allergies, depression, anxiety and sleep loss among the conditions that can come with it.
• The NIAMS Atopic Dermatitis: Diagnosis, Treatment, and Steps to Take page (last reviewed November 2022) says a doctor may need to see a patient several times to make an accurate diagnosis, that the treatment plan depends on the location, type and severity of the rash and the patient’s age, and that special baths or wraps should be used only after talking with the doctor.
• The MedlinePlus Eczema page (last updated June 15, 2025) says eczema is a term for several different types of skin swelling, that it is not contagious, that its cause is unknown, and that treatments may include medicines, skin creams, light therapy and good skin care. The MedlinePlus Psoriasis page (last updated February 20, 2019, older than two years) says psoriasis can be hard to diagnose because it can look like other skin diseases.
• The MedlinePlus encyclopedia article Psoriasis (review date August 5, 2024) says psoriasis isn’t contagious, that it can be a lifelong condition that can generally be controlled with treatment, and that it may go away for a long time and then return. The encyclopedia article Atopic dermatitis (review date October 13, 2024) lists skin infections, permanent scars and side effects from long-term use of medicines among the complications, and says to contact a provider for signs of infection such as fever, redness or pain.

Three of these pages are older than two years, and two of them say there is no cure. Before relaying that line, we checked for anything newer. A search of FDA drug label data through openFDA on October 30, 2026 returned labels updated as recently as September 2026 that list psoriasis or atopic dermatitis among their indications, including newer pills, injections and creams; they are labelled for treatment of the condition, and none we found describes a cure for either one. The agency wording on cure therefore still stands, and a page can say that newer treatments exist without naming them. Run the same check at each review.

Two points shape the marketing. First, both conditions are long-lasting and come and go, so a page that promises skin that stays clear says more than any source here. Second, both carry real weight beyond the skin, from sleep loss to joint damage to depression, and a page can name that weight honestly without using it to frighten people into booking.

Cure, clear skin and “gone for good” claims

Google’s search suggestions, which we checked on October 30, 2026, offer “psoriasis cure permanently”, “psoriasis cure cream” and “psoriasis curable” to a person who starts typing “psoriasis cure”, “is eczema contagious” and “is eczema curable” after “is eczema”, and “psoriasis treatment near me” and “eczema clinic near me” for the local searches. A clinic page can answer those questions honestly: quote NIAMS that there is no cure and that treatment can keep symptoms under control, say both conditions can flare and calm down, say neither one spreads from person to person, and say the plan depends on the type, severity and location of the disease.

Phrases that need rewriting:

• “We cure psoriasis.” NIAMS says there is currently no cure. Remove it, and describe control of symptoms in the agency terms.
• “Clear skin for good.” A result and permanence promise the sources contradict; MedlinePlus says psoriasis may go away for a long time and then return. Remove it.
• “Eczema gone in 30 days or your money back.” A timed results promise. Remove it, and state any refund terms on their own.
• “Your child will outgrow it.” NIAMS says it goes away before the teenage years for a large number of children and continues for others. Quote the agency line and remove the promise.
• “The root cause of eczema, finally fixed.” MedlinePlus says the cause of eczema is unknown. Remove it.
• “The newest breakthrough shot clears 100 percent of patients.” An outcome number with no source and an implied brand. Remove it, and name no product.

Under 15 U.S.C. 45, deceptive acts or practices in commerce are unlawful, and 15 U.S.C. 52 prohibits false advertisements likely to induce the purchase of drugs, devices, services or cosmetics. The FTC staff Health Products Compliance Guidance says claims about the health benefits or safety of health-related products require competent and reliable scientific evidence, and that an advertiser is responsible for the claims its ads convey, including implied ones. “Finally comfortable in your own skin” is a health benefit claim even without a number.

Emergency signs and 911 on every page and in every tool

A skin clinic does not think of itself as an emergency line, but it will receive urgent messages anyway. The MedlinePlus encyclopedia Psoriasis article (review date August 5, 2024) says to go to the emergency room or call 911 or the local emergency number for a severe outbreak that covers the whole body or a large part of it, and to tell the provider about joint pain or fever with psoriasis attacks. The Atopic dermatitis article (review date October 13, 2024) says to contact the provider for signs of infection such as fever, redness or pain, or when symptoms get worse or treatment does not work.

Put a short line above the booking button: if a rash suddenly covers the whole body or a large part of it, call 911 or go to the emergency room. Add a second line for the clinic’s own number: for fever, spreading redness, pain or a rash that is getting worse on treatment, call [phone]. The same wording belongs in voicemail, portal replies, text replies, chat and AI front desk tools, and a tool should never offer the next open slot weeks away to a person who describes those signs. Our guides to the AI chatbot on a practice website and answering service versus AI receptionist cover how tools hand off these messages.

Phrases that need rewriting:

• “Rash all over and a fever? Book your next available visit online.” Put the 911 line and the clinic’s number first, and the booking form after it.
• “Stop your current cream and try ours.” Treatment changes belong to the prescriber. Remove it, and say the clinician reviews treatment with the patient.
• “Message us any time.” Say who reads messages, during which hours, that the inbox is not watched around the clock, and give 911 for emergencies.

Creams, washes and “steroid-free” products: cosmetic or drug

Psoriasis and eczema clinics may sell moisturizers, washes and creams at the front desk or online, and the wording on those products decides how the law treats them. The FDA page Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) (content current as of September 11, 2024) says whether a product is a cosmetic or a drug is determined by its intended use, that the law defines drugs in part as articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease, and that skin moisturizers are among the products in the cosmetic definition. It says intended use can be established by claims on the labeling, in advertising, on the internet or in other promotional materials, and that certain claims may cause a product to be considered a drug even if it is marketed as a cosmetic.

For a clinic, that means a plain moisturizer described as keeping skin soft stays on the cosmetic side, while the same jar described as treating eczema or psoriasis is making a drug claim. Over the counter drug products and prescription products have their own labeling rules; describe them as labelled, and keep brand names off the clinic’s marketing pages.

Phrases that need rewriting:

• “Our natural cream heals eczema.” A disease claim that makes the product a drug under FDA’s intended use test. Remove it, or sell the product as a moisturizer only.
• “Steroid-free, so it’s totally safe for babies.” A safety claim with no evidence, and it implies prescribed treatment is unsafe. Remove it, and say parents should ask the clinician what to use on their child.
• “Our clinic-only serum repairs the skin barrier and stops flares.” A structure and disease claim. Describe what the product is and how to use it, and leave treatment claims to the clinician’s visit.

Light treatment, devices and supplements

NIAMS lists light treatment in the office among the options for psoriasis and for severe atopic dermatitis, and says a doctor may also prescribe a home light unit. The FDA page Premarket Notification 510(k) (content current as of August 22, 2024) says a 510(k) shows that a device is substantially equivalent to a legally marketed device, and that FDA’s order finding it so “clears” the device for commercial distribution. Under 21 CFR 807.97, any representation that creates an impression of official approval of a device because of complying with the premarket notification regulations is misleading and constitutes misbranding. NIAMS also says too much sunlight can make psoriasis worse, so a page should not suggest tanning beds or unsupervised light as a home fix. Our guides to medical device marketing claims and cryotherapy and red light claims cover intended use in full.

Supplements and diets sold as skin cures raise the same problem. The FDA Questions and Answers on Dietary Supplements (content current as of August 27, 2026) says FDA does not have the authority to approve dietary supplements before they are marketed. NIAMS says eating a healthy diet is one step people can take and that a Mediterranean diet has been shown to be helpful in several psoriasis studies; a page can quote that line with its date, but not turn it into a cure. Name no product and make no disease claim; our guide to selling supplements in a medical practice covers the rules if the clinic sells them.

Phrases that need rewriting:

• “FDA-approved light therapy that clears psoriasis.” Wrong word for a 510(k) device and a result promise. Say FDA cleared, for the use in its clearance, if that is true.
• “Our anti-inflammatory diet reverses eczema.” A disease claim with no source. Quote NIAMS on diet as written, and remove the promise.
• “Gut detox kit for psoriasis.” A disease claim for a product. Remove it.

Free skin checks, prices and coverage

Free eczema or psoriasis consultations at health fairs and school events are a familiar channel. A “free” consult follows 16 CFR 251.1, which says a free offer must not be recouped through a raised price or a reduced quantity or quality elsewhere, and the terms of the offer should be stated at the outset. A look at the skin at an event is not a diagnosis, and NIAMS says a doctor may need several visits to make one. Our guide to health fair screening events covers the event side.

Self-pay packages for light treatment sessions or skin care programs belong on the page in plain terms, with what is included and the refund terms. Our guides to advertising cash prices and good faith estimates for self-pay patients cover how to state a price and what uninsured and self-pay patients must receive. Say how the clinic checks coverage, and do not say a treatment “is covered” before it has been checked for the patient’s plan.

Drug makers, referrals and partners

Psoriasis and eczema clinics draw partners: primary care and pediatric offices, allergy practices, specialty pharmacies, home light unit suppliers and drug makers with patient support programs. Under 42 U.S.C. 1320a-7b(b), the federal anti-kickback statute, it is a crime to knowingly and willfully offer, pay, solicit or receive any remuneration to induce or reward referrals of items or services payable by a federal health care program. Rules on referral fees are also set state by state. Our guide to patient and physician referrals covers the general rules.

For a psoriasis or eczema clinic, keep these points:

• Do not accept payments, free staff or marketing help from a drug maker or pharmacy tied to the number of prescriptions written or sent, without counsel’s review. Our guide to Open Payments covers reported payments from manufacturers.
• Copay and patient support programs carry their own limits for patients in federal programs; our guide to rheumatology practice marketing covers how to describe them.
• Home light units and supplies go through the patient’s choice of supplier; our guide to DME supplier marketing covers the supplier side.
• Talks at schools and community centers follow our guide to patient education seminars, and research studies follow our guide to clinical trial recruitment ads.
• Clinics that see Medicaid patients follow the rules in our guide to marketing to Medicaid patients.

Privacy, pixels and ads

A visit to a psoriasis page, a skin quiz or a consult request says something about a person’s health, and a form that asks about joint pain, mood or a child’s sleep says more. Keep form answers, bookings and page clicks out of tracking pixels and ad platform tools unless a written agreement covers them; our guide to tracking pixels on practice websites covers the setup. The Google Ads personalized advertising policy lists health among its sensitive interest categories and restricts targeting based on it. Ads can target by place and by search terms, and should not be built from a list of patients with psoriasis or eczema.

Under 45 CFR 164.501, a reminder about the practice’s own treatment for an individual, such as a follow-up after light treatment, can fall outside the definition of marketing, while a message that promotes a third party’s product, such as a drug maker’s program or a skin care brand, generally needs a signed authorization under 45 CFR 164.508. Reminder texts name no condition, no result and no product in the message text.

Photos and patient stories

Before and after photos are the strongest pull in skin care marketing, and the hardest to use fairly for a condition that comes and goes. A photo taken during a calm stretch can show a result that the next flare undoes. Under 16 CFR 255.2, an ad that shows one person’s result on a key attribute is likely to be read as what others will generally achieve, unless the advertiser has substantiation for that or clearly and conspicuously discloses what people can generally expect. If photos are used, say how long after treatment each was taken, show the same lighting and angle, do not retouch the skin, and add a plain line that psoriasis and eczema can flare again.

Get a signed authorization under 45 CFR 164.508 where the practice is a covered entity, and consent for any photo or video. A child’s photo needs a parent’s or guardian’s signature and extra care, since skin photos can be identifying. Name no medicine or product, say if the patient received anything for taking part, and let them review the final version. Our guides to patient photo consent and testimonials and before and after photos cover the full rules.

Illustration: two psoriasis and eczema clinic pages

Illustration: a page reads “We cure psoriasis and eczema. Clear skin for good, with our FDA-approved light therapy and steroid-free natural cream that’s totally safe for babies. Your child will outgrow it with us. Rash all over and a fever? Book your next available visit online.” It claims a cure the agencies say does not exist, promises permanence, calls a cleared device approved, makes a drug claim for a cream, promises an outcome for a child, and puts a booking link where the 911 line belongs.

Illustration: a second page for the same practice reads “If a rash suddenly covers your whole body or a large part of it, call 911 or go to the emergency room. For fever, spreading redness, pain or a rash that is getting worse on treatment, call [phone]. At [Practice name], [Clinician name, license] sees adults and children with psoriasis and eczema. There is no cure yet for either one, but treatment can keep symptoms under control, and newer options keep arriving. Your plan depends on the type, how severe it is and where it is on your body. We also ask about joints, sleep and mood. Call [phone] during [days and hours].” It puts the emergency line first, quotes what the sources say, and promises nothing it cannot show.

Checklist before a psoriasis or eczema campaign goes live

• NIAMS and MedlinePlus pages named and dated, with pages older than two years marked as older and checked against newer FDA label data at each review.
• The 911 line for a rash covering the whole body or a large part of it above any booking button, plus the clinic’s number for fever, spreading redness, pain or worsening rash, in voicemail, portal replies, text replies, chat and AI front desk tools.
• No cure, clear skin or permanence claims; control of symptoms, flares and remission described in the agency terms.
• No promise that a child will outgrow eczema; the NIAMS line quoted as written.
• Creams and washes sold as cosmetics make no disease claims; no safety claims such as “steroid-free so it’s safe”; no brand names.
• Light devices described as FDA cleared only where true and only for the cleared use; no tanning or unsupervised sun advice.
• No supplement or diet cure claims; the NIAMS diet line quoted with its date, if used.
• Free consults follow 16 CFR 251.1 and say what they include; package prices and refund terms stated; coverage stated as checked.
• No payments, free staff or marketing help from drug makers, pharmacies or suppliers tied to prescriptions or orders without counsel’s review.
• Form answers and bookings stay out of pixels and ad audiences; targeting by place and search terms only.
• Photos have signed authorizations, consistent lighting, no retouching, the time since treatment and a line that flares can return; stories make no results claim.

How we help

We build websites, local search, Google Ads and AI front desk tools for independent practices and health businesses, including dermatology, allergy, pediatric and rheumatology practices that run psoriasis and eczema programs. For a skin condition clinic, that means a site that quotes NIAMS and MedlinePlus as written and dated, puts the 911 line and the clinic’s number above the booking button, answers “psoriasis cure” and “is eczema curable” searches without a promise, and keeps product pages on the right side of the cosmetic and drug line, plus booking and consult request pages that keep answers off the web and away from tracking tools. Our front desk tools hand urgent messages to the 911 line and the on-call number, and do not triage symptoms. We do not decide who needs treatment; your clinicians do. Our tools are built with HIPAA in mind. We confirm in writing what a BAA covers before any patient information flows through a tool, and if it is not covered, we do not route patient information through it. We are not a healthcare provider and we do not give legal or medical advice. We do not sell lead lists and we do not pay for referrals. For the wider rules, see our healthcare marketing rules hub.

Sources

• NIAMS: Psoriasis (last reviewed October 2023)
• NIAMS: Psoriasis: Diagnosis, Treatment, and Steps to Take (last reviewed October 2023)
• NIAMS: Psoriatic Arthritis (last reviewed August 2024)
• NIAMS: Atopic Dermatitis (last reviewed November 2022)
• NIAMS: Atopic Dermatitis: Diagnosis, Treatment, and Steps to Take (last reviewed November 2022)
• MedlinePlus: Psoriasis (last updated February 20, 2019)
• MedlinePlus: Eczema (last updated June 15, 2025)
• MedlinePlus encyclopedia: Psoriasis (review date August 5, 2024)
• MedlinePlus encyclopedia: Atopic dermatitis (review date October 13, 2024)
• openFDA: Drug labeling API (searched October 30, 2026)
• FDA: Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) (content current as of September 11, 2024)
• FDA: Premarket Notification 510(k) (content current as of August 22, 2024)
• 21 CFR 807.97: Misbranding by reference to premarket notification
• FDA: Questions and Answers on Dietary Supplements (content current as of August 27, 2026)
• 15 U.S.C. 45: Unfair methods of competition unlawful
• 15 U.S.C. 52: Dissemination of false advertisements
• FTC: Health Products Compliance Guidance (December 2022)
• 16 CFR 251.1: Guide concerning use of the word free and similar representations
• 42 U.S.C. 1320a-7b: Criminal penalties for acts involving Federal health care programs
• 45 CFR 164.501: Definitions
• 45 CFR 164.508: Uses and disclosures for which an authorization is required
• 16 CFR 255.2: Consumer endorsements
• Google Ads: Personalized advertising policy

More in Physician specialty marketing